Research Article, March 2016
A national, multi institutional, Phase Ia,b clinical trial of p28 as a single agent in pediatric patients with recurrent or progressive CNS tumors sponsored by the Pediatric Brain Tumor Consortium (PBTC-041) and the NCI-CTEP was published in Neuro-Oncology.
Phase 1 trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.
Neuro Oncol., 2016 Mar 28. pii: now047. [Epub ahead of print]